RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $15
RBC Capital has reaffirmed its Buy rating on Wave Life Sciences (WVE.US) but has reduced the price target to $15. This adjustment reflects an updated assessment by the firm while still maintaining a positive outlook on the company's stock.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts
WAVE Life Sciences (NASDAQ:WVE) has received an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $31.38. This comes despite the company reporting a Q4 EPS miss and a negative net margin. Insider activity shows recent stock sales by Chandra Vargeese and Chris Francis, although insiders still retain a significant holding of 23.98%.
A Look At Wave Life Sciences (WVE) Valuation After INLIGHT Phase 1 Obesity Data Disappoints Investors
Wave Life Sciences (WVE) shares recently sold off after interim Phase 1 data for its obesity candidate WVE-007 disappointed investors, despite showing clinically meaningful reductions in visceral fat and waist circumference. While the stock experienced a short-term bounce, it remains significantly down over the past 30 days and year-to-date. The article suggests that WVE is currently undervalued at $7.28 compared to an average analyst target of $26.53 and a narrative fair value of $34.06, anticipating future clinical and revenue milestones, but acknowledges risks associated with clinical trials and current unprofitability.
Wave Life Sciences (WVE) Is Up 14.4% After Phase 1 Data On Long‑Acting Obesity Drug WVE‑007
Wave Life Sciences (WVE) stock rose 14.4% following positive interim Phase 1 INLIGHT data for its long-acting obesity drug, WVE-007. The drug showed significant, six-month reductions in visceral fat and waist circumference with preserved lean mass, outperforming weekly semaglutide in visceral fat-to-muscle ratio improvement among patients with higher average BMI. This strengthens the company's investment narrative and precedes a planned Phase 2a trial in Q2 2026 for patients with higher BMI and comorbidities.
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history
This article provides a detailed financial overview of Wave Life Sciences Ltd. (WVE), including its stock price, historical performance, key financial metrics, and analyst insights. It covers the company's business in biotechnology, its therapeutic development pipeline, and collaboration agreements. The information presented includes stock charts, market capitalization, earnings trends, valuation measures, and comparisons with similar companies in the industry.
Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise
Shares of Wave Life Sciences (WVE) dropped after initial Phase 1 clinical trial data for its weight loss drug, WVE-007, showed only a 1% body weight reduction over six months. Despite this, the drug demonstrated a significant 14% reduction in visceral fat and a 2% increase in lean body mass, suggesting a differentiated approach to weight loss by targeting the most dangerous fat while preserving muscle. Although the company faces further clinical and regulatory hurdles and carries high risk due to minimal revenue, the market's negative reaction might be an overreaction given the drug's potential to address a critical aspect of obesity.
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?
Wave Life Sciences (WVE) stock rose 9.5% to $7.25 with notable trading volume, rebounding after a 52.2% loss over the past four weeks due to mixed interim obesity study results. Despite its recent gain, a negative trend in earnings estimate revisions suggests caution, as the company is expected to post a quarterly loss of $0.34 per share. The stock currently holds a Zacks Rank #3 (Hold), indicating that while it may not be a strong buy, it should be monitored for future performance.
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13
Wells Fargo has reiterated its Buy rating on Wave Life Sciences (WVE.US) but has adjusted its price target downwards to $13. This revision comes after the bank previously held a different price target, indicating a re-evaluation of the company's financial outlook despite maintaining a positive stance on its stock.
JPMorgan Chase & Co. Has $6.30 Million Position in WAVE Life Sciences Ltd. $WVE
JPMorgan Chase & Co. reduced its stake in WAVE Life Sciences Ltd. by 45.2% during the third quarter, selling 708,874 shares and now holding 860,141 shares valued at approximately $6.30 million. Despite analysts issuing "Moderate Buy" ratings with a consensus target of $31.38, the company missed EPS estimates in its latest quarterly earnings report, and insiders sold over $900,000 worth of stock. Institutional investors collectively own nearly 90% of the company's shares.
[SCHEDULE 13D/A] Wave Life Sciences Ltd. Amended Major Shareholder Report
RA Capital and its affiliates have significantly increased their stake in Wave Life Sciences Ltd. (WVE), now beneficially owning 34,225,506 ordinary shares, which represents 17.5% of the company's outstanding shares. This amended Schedule 13D/A filing details multi-million share purchases made in late March 2026 at weighted-average prices between $6.06 and $6.50 per share, funded by the RA Capital Healthcare Fund's working capital. The ownership stake also includes ordinary shares issuable upon the exercise of pre-funded warrants.
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review
Canaccord Genuity has raised its price target for Wave Life Sciences Ltd. (WVE) to $52 from $43, maintaining a Buy rating after reviewing the company's pipeline and fresh financial models. This positive update also followed the company's announcement that data from its RestorAATion-2 clinical trial for WVE-006 (AATD) would be presented at the ATS International Conference, with regulatory feedback for potential accelerated approval anticipated in mid-2026. Wave Life Sciences is also expected to release INLIGHT trial data for WVE-007 targeting obesity later this month.
Wave Life Sciences shares plunge 30% despite encouraging obesity trial results
Wave Life Sciences (WVE) shares dropped 30% despite reporting encouraging early trial results for its obesity and cardiometabolic disorder drug, WVE-N531. The preclinical data showed significant improvements in weight loss, glucose tolerance, and cholesterol levels in mice. However, the market's negative reaction may stem from the competitive landscape of obesity drugs and the early stage of WVE-N531's development.
StockWatch: Wave Plummets 50% on Obesity Data
Wave Life Sciences (NASDAQ: WVE) shares dropped roughly 50% after releasing mixed early-stage clinical data for its obesity drug candidate, WVE-007. The drug showed less than a 1% reduction in body weight and a 3.3% decline in waist circumference, which disappointed investors compared to FDA benchmarks. Despite this, the company highlighted improvements in visceral and total fat reduction, and analysts expressed both caution and continued optimism regarding the drug's potential for specific fat reduction and infrequent dosing.
Wave Life Sciences Slips as Obesity Data Fails to Convince
Wave Life Sciences (WVE) stock dropped significantly after two Wall Street firms cut their price targets, citing insufficient data from the Phase 1 INLIGHT trial for WVE-007 as a standalone obesity treatment. While the trial showed a 14.3% placebo-adjusted visceral fat reduction, concerns were raised about the study population's lower BMI compared to typical obesity studies and the conviction in the liver Activin E knockdown mechanism. The company plans to initiate Phase 2a in Q2 2026 with higher BMI patients to further demonstrate efficacy.
Wave Life Sciences Slips as Obesity Data Fails to Convince
Wave Life Sciences (WVE) shares sharply declined after updated Phase 1 INLIGHT trial data for its obesity candidate, WVE-007, failed to impress investors and analysts. Despite showing a 14.3% placebo-adjusted visceral fat reduction, concerns arose because the study population had lower BMIs than typical obesity trials, leaving its efficacy as a standalone treatment in higher BMI patients unproven. Financial firms BofA and Wells Fargo subsequently cut their price targets for the stock, emphasizing the need for more compelling data.
WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal
WAVE Life Sciences announced positive interim Phase 1 data for WVE-007, an investigational GalNAc-siRNA targeting obesity. The therapy demonstrated significant, durable visceral fat reduction (14.3% at six months) and preservation of lean muscle mass with a favorable safety profile. These results suggest WVE-007 could offer an "orthogonal" approach to obesity treatment, potentially allowing for once- or twice-yearly dosing, and the company plans to initiate a multiple-dose Phase 2a trial in Q2 2026.
Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?
Wave Life Sciences (NASDAQ:WVE) shares dropped sharply after the announcement of interim Phase 1 data from its INLIGHT trial for WVE-007, despite positive six-month data showing significant reductions in visceral fat and stability in lean mass. The stock is experiencing significant bearish pressure, trading well below its moving averages, even though analysts have recently raised price targets with "Buy" ratings.
Wave Life Sciences Faces Major Revenue Crunch in Latest Financial Report
Wave Life Sciences (NASDAQ: WVE) stock has dropped by 56.12% after its Q4 financial report revealed a loss of $0.30 per share, exceeding the forecasted loss of $0.26. Although revenue beat expectations at $17.2 million, it significantly decreased from $83.7 million in the previous year, indicating a major decline in income. The company's shift from a Q4 profit last year to a substantial loss this year highlights its current financial struggles despite a slight premarket stock bump.
Wave Plunges After Shot’s Fat-Reduction Misses Expectations
Wave Life Sciences (WVE) shares experienced a significant drop after its experimental weight-loss drug, WVE-007, did not meet investor expectations for reducing visceral fat in a high-dose shot. The drug aims to offer a less frequent treatment option for obesity without causing muscle loss, a known side effect of existing blockbuster medications. WVE-007 works by targeting a gene associated with obesity and is designed for annual or biannual administration.
Wave Life Sciences plunges after early-stage data for obesity therapy
Wave Life Sciences' stock (WVE) dropped significantly by 57% in premarket trading after interim data from an early-stage trial for its RNA-based obesity medicine, WVE-007, was released. The company is reacting to six-month follow-up data from its INLIGHT trial involving healthy individuals.
Wave Life Sciences Shares Plunge 55% Despite Positive Early Trial Data
Wave Life Sciences Ltd. (WVE) saw its shares plummet over 55% despite reporting positive interim results from its Phase 1 INLIGHT trial for WVE-007, which showed significant improvements in body composition. The stock's decline suggests investor concerns about the early stage of the trial, future development risks, or that expectations were already factored into the price. The company plans to begin the Phase 2a portion of the INLIGHT study in Q2 2026.
One dose cut visceral fat 14% after 6 months while preserving muscle
Wave Life Sciences announced positive interim Phase 1 data for its investigational drug WVE-007, showing a 14.3% placebo-adjusted reduction in visceral fat and preservation of lean muscle mass at six months after a single dose. These results, seen in individuals with lower BMI than typical obesity studies, suggest WVE-007's potential for treating obesity and related cardiometabolic conditions, with a Phase 2a study planned for Q2 2026 in higher BMI patients. The drug was generally well-tolerated and demonstrated durable Activin E suppression, supporting potential once or twice-yearly dosing.
Wave Life Sciences Announces Positive Interim Phase 1 Data
Wave Life Sciences announced positive interim Phase 1 data for WVE-007, an investigational INHBE GalNAc-siRNA, showing further improvements in body composition, including significant reductions in visceral fat and waist circumference, with muscle preservation. These results were observed six months after a single dose in individuals with overweight or obesity. The company plans to initiate the Phase 2a portion of the INLIGHT trial in Q2 2026 to further evaluate WVE-007 in individuals with higher BMI and comorbidities, with potential applications in obesity, MASH, type 2 diabetes, and cardiovascular disease.
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
Wave Life Sciences announced positive interim Phase 1 data for WVE-007, an investigational INHBE GalNAc-siRNA, showing significant reductions in visceral fat and waist circumference, and preservation of lean mass at six months following a single dose. These results were observed in individuals with lower BMI than typically enrolled in obesity studies, suggesting even greater improvements for higher BMI patients in the upcoming Phase 2a trial. The data also indicate potential for WVE-007 to treat MASH, type 2 diabetes, and cardiovascular disease, with plans for further clinical trials including as an incretin add-on.
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
Wave Life Sciences announced positive interim Phase 1 data from its INLIGHT trial for WVE-007, showing significant placebo-adjusted reductions in visceral fat and waist circumference, along with lean mass preservation, six months after a single dose. These results in individuals with lower BMI suggest greater improvements are possible in higher BMI populations. The company plans to initiate a Phase 2a study in Q2 2026 and explore WVE-007 for obesity, MASH, type 2 diabetes, and cardiovascular disease.
Jefferies reiterates Buy on Wave Life Sciences stock ahead of May data
Jefferies has reiterated a Buy rating and a $28.00 price target for Wave Life Sciences (NASDAQ:WVE), based on the company's RNA editing approach for alpha-1 antitrypsin deficiency. The stock currently trades at $12.20, indicating significant upside potential. Upcoming data presentations in May for their WVE-006 program are anticipated to show favorable results, supporting potential regulatory discussions in 2026.
WVE: Mizuho Maintains Outperform, Raises Price Target to $27 | WVE
Mizuho has reiterated its "Outperform" rating for Wave Life Sciences (WVE) and increased its price target from $22.00 to $27.00, signaling continued confidence in the stock's growth potential. This adjustment follows several other analyst upgrades for WVE in early 2026. The average one-year price target from 16 analysts for WVE is $35.13, suggesting a significant upside from its current price, although GuruFocus estimates a lower GF Value.
WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $27.00 at Mizuho
Mizuho has increased its price target for WAVE Life Sciences (NASDAQ:WVE) to $27.00 from $22.00, maintaining an "outperform" rating and implying a 117% upside. The company trades around $12.42 with a $2.34 billion market cap, recently missed quarterly EPS estimates, and has seen insider selling. Despite these factors, analysts generally have a "Moderate Buy" consensus rating with an average target of $33.31.
Mizuho raises Wave Life Sciences stock price target on obesity drug progress
Mizuho increased its price target for Wave Life Sciences (NASDAQ:WVE) shares to $27 from $22, maintaining an Outperform rating, due to progress in its obesity drug pipeline. The company is expected to release further fat loss data for WVE-007 and initiate a Phase 2a multidose trial in the first half of 2026, alongside other planned clinical trial applications and an NDA submission. Despite a year-to-date stock decline, the company holds a "Strong Buy" consensus recommendation and a "Fair" financial health score.
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 earnings call transcript
This document is a transcript of Wave Life Sciences Ltd.'s Q4 2025 earnings call. It contains detailed discussions related to the company's financial performance and operational updates for the fourth quarter of 2025.
WAVE Life Sciences teams prepare to share development insights at OPTBoston
WAVE Life Sciences is participating in OPTBoston this week, where its team will share expertise across various sessions from discovery to development. The company aims to foster dialogue about translating scientific advances into real-world applications and strengthen industry connections. This involvement aligns with WAVE Life Sciences' ongoing commitment to addressing unmet medical needs through scientific innovation and collaboration.
Cinctive Capital Management LP Lowers Holdings in WAVE Life Sciences Ltd. $WVE
Cinctive Capital Management LP significantly reduced its stake in WAVE Life Sciences Ltd. by 60.2% in the third quarter of the prior year, selling over 167,000 shares. This comes as company insiders have also been selling stock, totaling over 61,000 shares worth $907,809 in the last 90 days. Despite these sales, analysts maintain a "Moderate Buy" consensus rating with an average target price of $33.73, while the company reported a Q4 revenue beat but an EPS miss.
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)
Healthcare analysts have issued bullish sentiments for Apogee Therapeutics (APGE), Wave Life Sciences (WVE), and Telix Pharmaceuticals (TLPPF). Wedbush maintained a Buy rating for Apogee Therapeutics with a $95 price target, and a Strong Buy consensus remains for the company. Wave Life Sciences also received a Buy rating from Wedbush with a $35 price target, supported by a Strong Buy consensus. Canaccord Genuity maintained a Buy rating for Telix Pharmaceuticals with a A$28.50 price target, also leading to a Strong Buy consensus.
Assessing Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Cash Runway Update
Wave Life Sciences (WVE) is drawing investor attention following positive interim Phase I data for its WVE-007 obesity candidate and an updated cash position expected to fund operations through 2026. Despite recent share price declines, the company is seen as undervalued with a fair value estimated at $33.50 against a current price of $13.35, driven by its RNA platform and pipeline. However, this valuation depends heavily on future trial readouts and increased losses from R&D spending could pose risks.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages
Brokerages have assigned WAVE Life Sciences Ltd. (NASDAQ:WVE) a consensus "Moderate Buy" rating, with 13 out of 14 analysts recommending a buy. The average 12-month price target is $33.73, and several firms have recently raised their targets. Despite this positive sentiment, the company reported a Q4 EPS miss and remains unprofitable with negative ROE and net margin.
WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has increased its price target for WAVE Life Sciences (NASDAQ:WVE) to $52.00 from $43.00, maintaining a "buy" rating, which implies a potential upside of nearly 268% from the current share price. While analyst consensus is a "Moderate Buy" with an average target of $33.73, the company recently missed EPS estimates and reports significant insider selling. WAVE Life Sciences is a clinical-stage genetic medicines company developing stereopure oligonucleotide therapies for serious diseases.
Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed
Wave Life Sciences (WVE) experienced a 5.8% drop after reporting wider losses in Q4 2025, with revenues significantly down from the previous year. Despite the financial setback, the company is advancing its clinical pipeline, particularly with WVE-006 for alpha-1 antitrypsin deficiency, by pursuing an accelerated approval pathway and presenting new data. This strategic regulatory push for WVE-006, alongside upcoming data for WVE-007 (obesity), is crucial for reshaping its investment narrative and mitigating the impact of increasing operational losses.
Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed
Wave Life Sciences (WVE) experienced a 5.8% drop after reporting wider losses in Q4 2025 and decreased annual revenues, with sales down to US$17.24 million from US$83.75 million a year prior. Despite these financial setbacks, the company is advancing its WVE-006 program by pursuing an accelerated approval pathway for alpha-1 antitrypsin deficiency and securing a late-breaking oral presentation slot at the American Thoracic Society conference. This strategic move aims to recalibrate its investment narrative and risk profile, hinging on clinical and regulatory clarity for WVE-006 and WVE-007.
Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed
Wave Life Sciences (WVE) experienced a 5.8% drop after reporting wider losses in Q4 2025 with revenues down to US$17.24 million, replacing a prior net income. Despite the financial setback, the company is advancing its WVE-006 program for alpha-1 antitrypsin deficiency by pursuing an accelerated approval pathway and will present new data at the American Thoracic Society conference. This strategic move aims to recalibrate the investment narrative, balancing increased cash burn with potential regulatory clarity for WVE-006 and upcoming WVE-007 obesity data.
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
Wave Life Sciences Ltd. (Nasdaq: WVE) announced the acceptance of a late-breaking oral presentation for data from its RestorAATion-2 clinical trial of WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The presentation will include new data from both the 400 mg multidose cohort and the 600 mg single dose cohort at the American Thoracic Society (ATS) International Conference in May 2026. The company is also pursuing an accelerated approval pathway for WVE-006 and expects feedback mid-2026, while also planning to deliver data from its WVE-007 obesity trial this month.
WVE: Wedbush Raises Price Target for WAVE Life Sciences, Reaffirms 'Outperform'
Wedbush has increased its price target for WAVE Life Sciences (WVE) to $35.00 from $33.00, while maintaining an 'Outperform' rating, indicating continued confidence in the company. This follows several other analyst adjustments, with the average one-year price target for WVE standing at $34.13, suggesting a significant upside from its current price. WAVE Life Sciences is a clinical-stage biotechnology company focusing on RNA medicines for various rare and prevalent diseases.
Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates
Wave Life Sciences (WVE) has recently presented updates on its RNA editing and obesity programs, including new clinical data for WVE-006 and trial plans for WVE-007. Despite recent short-term share price dips, the company shows strong long-term momentum and is considered undervalued with a narrative fair value of $33.38 against a closing price of $13.20. The company's expansion into new pipeline candidates and proprietary RNA platforms are seen as drivers for future growth, though rising losses and reliance on binary clinical programs present risks.
Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference
Wave Life Sciences has announced that a late-breaking oral presentation on its investigational therapy WVE-006 for alpha-1 antitrypsin deficiency (AATD) has been accepted for the American Thoracic Society (ATS) International Conference. This highlights the company's commitment to developing RNA medicines and advancing its pipeline, which also includes clinical programs for Duchenne muscular dystrophy and Huntington's disease, and a preclinical program for obesity. The presentation signifies continued progress in addressing rare and prevalent disorders through its PRISMTM RNA medicines platform.
Experimental RNA treatment for alpha-1 gets late-breaking lung conference slot
Wave Life Sciences announced that its experimental RNA treatment WVE-006 for alpha-1 antitrypsin deficiency (AATD) will be featured in a late-breaking oral presentation at the American Thoracic Society International Conference in May 2026. The presentation will include new data from the RestorAATion-2 trial's 400 mg multidose and 600 mg single-dose cohorts. The company is also seeking regulatory feedback on an accelerated approval pathway for WVE-006 and expects WVE-007 obesity trial data this month.
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
Wave Life Sciences announced that its late-breaking oral presentation on WVE-006 for alpha-1 antitrypsin deficiency (AATD) has been accepted at the upcoming American Thoracic Society (ATS) International Conference. The presentation will include new data from both the 400 mg multidose and 600 mg single-dose cohorts of the RestorAATion-2 clinical trial. The company is also advancing regulatory engagement for a potential accelerated approval pathway for WVE-006 and expects feedback by mid-2026.
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside
Wave Life Sciences (NasdaqGM:WVE) announced positive Phase I proof of concept for its obesity candidate, WVE-007, showing fat loss with muscle preservation. This news, along with progress in other RNA editing programs (WVE-006 and WVE-008), is shifting investor focus to the company's robust pipeline. While the stock has seen significant long-term gains, recent performance has been mixed, highlighting the importance of upcoming Phase II trials and regulatory milestones.
WVE SEC Filings - Wave Life Scienc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Wave Life Sciences (WVE) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details recent filings such as proposed share sales, major investor disclosures, and outcomes of the company's Annual General Meeting, including an increase in the equity incentive plan. The platform also offers AI-powered summaries to quickly highlight key points from these regulatory documents.
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside
Wave Life Sciences announced positive Phase I results for its obesity candidate WVE-007, showing fat loss and muscle preservation, and is preparing for a Phase II trial. The company's RNA editing programs for alpha-1 antitrypsin deficiency and liver disease are also advancing, drawing investor attention to the pipeline's future development and potential partnerships. Despite recent stock price fluctuations, the company trades significantly below analyst targets, with a focus on upcoming trial designs and regulatory milestones.
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story
Wave Life Sciences (WVE) reported mixed Q4 2025 results, with falling revenue and increased net loss, yet highlighted positive interim obesity and alpha-1 antitrypsin deficiency data. The company's cash position of US$602.10 million is projected to fund operations into 2028, and an expanded collaboration with GSK could yield up to US$2.80 billion, supporting its RNA-based pipeline despite widening net losses and dependence on future fundraising. The investment narrative largely depends on the success of upcoming WVE-007 obesity and WVE-006 AATD data readouts.
Artisan Partners Limited Partnership Trims Stake in WAVE Life Sciences Ltd. $WVE
Artisan Partners Limited Partnership significantly cut its stake in WAVE Life Sciences Ltd. by 45.6% during the third quarter, reducing its holdings to 1.23 million shares valued at approximately $9.0 million. This move comes amid recent substantial insider selling, with executives disposing of nearly 948,375 shares worth $14.1 million. Despite a negative sentiment from insider sales and an earnings miss, the company has a near-term catalyst with upcoming data updates for its INHBE obesity program in Q1 2026.
